54 results about "Aerosol drug delivery" patented technology

Sterile compositions for administration as aerosols are described. They contain an active agent which is poorly water-soluble, a non-ionic surfactant acomponent and a phospholipid component. The compositions are suitable for oral or nasal inhalation, but also for topical or oromucosal administration. They are particulary useful for the efficient pulmonary administration of poorly soluble corticosteroids and can be aerosolized with common nebulizers.

A method and system is disclosed which is capable of delivering at a high dose rate, respirable solid aerosols derived from aqueous- or nonaqueous-based solutions containing the desired therapeutic agent(s). The method and system comprises the integration of an aerosol generator, an aerosol evaporator, an aerosol concentrator, and an aerosol flow regulator. The aerosol generator generates 10-30 μm droplets, with a narrow size distribution. The aerosol jet is arrested by a coaxial counter-flow heated air jet, and evaporated rapidly by annular swirling heated air. Most of the air, together with the unwanted solvent vapor, is removed from the aerosol stream during the process of aerosol concentration. The output aerosol carries the dry particles to be inhaled by the patient. The respiratory-governed control of aerosol fluid generation system delivers fluid containing the test agent of interest (drug or toxin) to the aerosol generator throughout inhalation.

Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.

This invention relates to tiotropium containing stable pharmaceutical solution formulations suitable for aerosol administration. More particularly, this invention relates to tiotropium containing stable pharmaceutical solution formulations suitable for aerosol administration wherein either an inorganic acid or an organic acid is added to the aerosol solution formulation which contains a tiotropium salt, preferably tiotropium bromide in solution with an environmentally safe hydrofluorocarbon (HFC) as a propellant, together with an organic compound as a cosolvent. The acid provides stability against degradation or decomposition of the medicament resulting largely from interaction of the medicament with the cosolvent and / or water present in the solution formulation.

An aerosolization device comprises a housing having a mouthpiece, and a flow path arrangement in fluid communication with the mouthpiece. The flow path arrangement has a flow regulating valve and a threshold valve, where the threshold valve is configured to open at a first vacuum level and to close at a second vacuum level that is less than the first vacuum level. The housing includes a region that is adapted to hold a powder in fluid communication with the flow path arrangement so that air drawn through the mouthpiece opens the threshold valve once the first vacuum level is exceeded and remains open until the vacuum falls below the second vacuum level. The flow rate of the air drawn through the mouthpiece is regulated by the flow regulating valve to remain within a certain range while the threshold valve remains open.

A portable air temperature controlling device useful for warming air surrounding an aerosolized drug formulation. Warming the air of an aerosol makes it possible to reduce the diameter of aerosol particles produced by an aerosol generation device. Additionally, warming the air forces the diameter of the aerosol particles to be in the range required for systemic drug delivery independent of ambient conditions. Smaller particles can be more precisely targeted to different areas of the respiratory tract.

In one aspect, the present invention features a method of administering nicotine or a salt thereof to a human, wherein the method includes inhaling an aerosol of a liquid formulation, the liquid formulation comprising: (i) at least 12 percent by weight of water; (ii) at least 70 percent by weight of propylene glycol; and (iii) at least 2 percent by weight of said nicotine or a salt thereof; wherein the liquid formulation includes no more than 5 percent by weight of glycerol and no more than 5 percent by weight of ethanol. The present invention also features an aerosol-generating device and a reservoir for such a device containing such a liquid formulation.

Face masks for use in pressurized drug delivery applications, such as aerosol drug delivery systems, and a method of reducing aerosol deposition in the region of the eyes are presented. The face masks according to the various embodiments disclosed herein contain features that reduce the inertia of the aerosolized drug in perinasal areas. This results in a reduction in the amount of aerosolized drug that is deposited in the region of the eyes by inertial impaction, while at the same time, the features are constructed to maintain the flow of the aerosolized drug into the face mask so that the aerosolized drug is effectively delivered to the respiratory system of the patient.

Face masks for use in pressurized drug delivery applications, such as aerosol drug delivery systems, and a method of reducing aerosol deposition in the region of the eyes are presented. The face masks according to the various embodiments disclosed herein contain features that reduce the inertia of the aerosolized drug in perinasal areas. This results in a reduction in the amount of aerosolized drug that is deposited in the region of the eyes by inertial impaction, while at the same time, the features are constructed to maintain the flow of the aerosolized drug into the face mask so that the aerosolized drug is effectively delivered to the respiratory system of the patient.

A drug delivery device containing a sterile multi dose reservoir. Said sterile reservoir can be used with many types of delivery including injectors or aerosol drug delivery systems. Elevated pressure surrounding the reservoir is used during storage to ensure sterility is maintained. Mechanisms to prevent delivery in the case of potential compromise of sterility are disclosed. A device using the pressure to meter formulation from the reservoir is disclosed.

Face masks for use in pressurized drug delivery applications, such as aerosol drug delivery systems, and a method of reducing aerosol deposition in the region of the eyes are presented. The face masks according to the various embodiments disclosed herein contain features that reduce the inertia of the aerosolized drug in perinasal areas. This results in a reduction in the amount of aerosolized drug that is deposited in the region of the eyes by inertial impaction, while at the same time, the features are constructed to maintain the flow of the aerosolized drug into the face mask so that the aerosolized drug is effectively delivered to the respiratory system of the patient.

Disclosed herein are formulations of nitrite, nitrite salt, or nitrite- or nitric oxide-producing compounds suitable for aerosolization and use of such formulations for aerosol administration of nitrite, nitrite salt, or nitrite- or nitric oxide-donating compounds for the treatment of pulmonary arterial hypertension, intra-nasal or pulmonary bacterial infections, or to treat or prevent ischemic reperfusion injury of the heart, brain and organs involved in transplantation. In particular, inhaled nitrite, nitrite salt, or nitrite- or nitric oxide-donating compound specifically formulated and delivered to the respiratory tract for the indications is described. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures and manufacturing processes for production and use of the compositions described.

An aerosol drug delivery apparatus is provided. The apparatus may include a reservoir constructed to contain a predetermined dose of a liquid drug, an aerosol generator in communication with the reservoir, and a power source arranged to deliver power to the aerosol generator in order to produce an aerosolized form of the dose that can be administered to a patient. The apparatus may maintain consistent aerosol drug delivery treatments, for example, by way of a breath measuring mechanism that monitors the patient's breathing pattern during the administration of the dose and a controller configured to vary the power level at which the power source during the administration of the dose based on the monitored breathing pattern.

A portable air temperature controlling device useful for warming air surrounding an aerosolized drug formulation is described. Warming the air of an aerosol makes it possible to reduce the size of aerosol particles produced by an aerosol generation device. Additionally, warming the air forces the size of the aerosol particles to be in the range required for systemic drug delivery independent of ambient conditions. Smaller particles can be more precisely targeted to different areas of the respiratory tract.

The invention provides a drug delivery vehicle for inhalation by a patient. The drug delivery vehicle comprises biocompatible particles between 0.1 and 1.0 microns in diameter, that are loaded with one or more drugs and which are crosslinked together to form agglomerates. The agglomerates can also provide for delivery of contrast-enhancing agents for clinical imaging. The invention also provides methods of making the inventive agglomerates, pharmaceutical compositions comprising the agglomerates, and methods for delivering drugs or contrast-enhancing agents to a patient by inhalation of pharmaceutical compositions containing the agglomerates.

A system and method of controlling the administration of a medical substance is disclosed. An aerosol generator is configured to aerosolize a medical substance and administer the aerosolized medical substance to a patient using a ventilator. The patient is provided with a patient control interface through which the patient initiates the administration of a dose of the aerosolized medical substance. A processor is configured to control the ventilator and the aerosol generator in response to the patient control interface such that the patient controls the administration of the aerosolized medical substance in accordance with limits on the administration of the medical substance.

A method of treating respiratory disorders by delivering antibiotic to the lung alveoli using an aerosol drug delivery system.

Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.

The invention provides aerosol for treating faucitis and a preparation method thereof. The aerosol is convenient to administrate, and has good curative effect of treating the faucitis, in particular treating hoarseness, aphonia and the like.

Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.

The invention discloses an aerosol feeder pushing button with a counter. The aerosol feeder pushing button comprises a pushing button, a cap body, a counter and a counter housing. The counter is arranged on an outer side wall of the pushing button. The counter comprises a counter base, a gear, a single-digit dial and a tens-digit dial. The counter base is inserted in the outer side wall of the pushing button. A fixed shaft is arranged on the outer side wall of the pushing button. The single-digit dial is sleeved on the outer side of the fixed shaft. The tens-digit dial is sleeved on the top ofthe single-digit dial . The counter base comprises a cantilever beam, an actuating rod below the cantilever beam and a connecting arm for connecting the cantilever beam and the actuating rod. The endof the actuating rod has an outward protruding end. The one end of the cantilever beam is connected to the counter base and the other end of the cantilever beam is impending. An actuating pawl is arranged at the impending end of the cantilever beam. By the arrangement, the aerosol feeder pushing button can solve the problem that an existing user of aerosol can not know usage count and remaining usage count of the aerosol.

Dual and triple therapy combinations of drugs formulated as brittle matrix particles with a high surface area are provided herein. These particle formulations may be used in inhalation or aerosol administration techniques to provide the drug combinations to the lungs. In some aspects, these compositions may be used to treat a respiratory disease or disorder such as asthma or COPD.

The present invention relates to an apparatus (10) to aid in administering inhaled pharmaceutical aerosol to a patient. The apparatus (10) is used in conjunction with an aerosol delivery device. The apparatus comprises steps (32, 34) on the top and bottom of the apparatus (10), which when used aid the patient causes mandibular advancement, and opening of the mouth, causing opening of patient's airway, resulting in improved aerosol lung deposition. The invention also relates to a method of using such apparatus in a combination with an aerosol delivery device or a system, and to the mouthpiece of said apparatus.

A device for administration of an aerosol includes a generator of particles of size between 10 nm and 200 um, a mouthpiece or mouth mask for oral administration of the aerosol during the nasal exhalation phase or during the respiratory pause phase preceding nasal exhalation, and a source of gas or pressure for conveying the particles. The mouthpiece is airtight, extends beyond the teeth of the patient by a maximum length of 4 cm, and administers the aerosol for the nasal cavities, the rhinopharynx or the paranasal sinuses during aerosol administration phases, such that the is successively applied to the mouth, the rhinopharynx and then the nasal fossae and the sinuses, and then the aerosol escapes via one or both of the patient's nostrils. The device does not allow exhalation via the mouth during aerosol administration phases, and the aerosol particles not being directed to the lungs.